On August 27, 2019 RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, reported that the Company will present a corporate overview at two investor conferences in September (Press release, RedHill Biopharma, AUG 27, 2019, View Source [SID1234539045]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Annual Healthcare Conference
Date: Monday, September 9, 2019
Time: 11:40 a.m. EDT
Speaker: Dror Ben-Asher, Chief Executive Officer
Location: Lotte New York Palace Hotel, NY

Ladenburg Thalmann 2019 Healthcare Conference
Date: Tuesday, September 24, 2019
Time: 1 p.m. EDT
Speaker: Guy Goldberg, Chief Business Officer
Location: Sofitel Hotel, NY

A copy of the presentations will be available on the Company’s website and may be viewed at: View Source